ClinicalTrials.gg
RecruitingNCT05363722Updated Nov 17, 2026

Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC

A Phase 1 interventional study of IBI310(1mg/kg) and sintilimab in Hepatocellular Carcinoma, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Zhongshan Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 17, 2026Now RecruitingFirst site in China+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies testing sintilimab in Carcinoma, Hepatocellular — 27 open to participants now, 31 under way, 5 of them phase 3. sintilimab · Carcinoma, Hepatocellular.

Planned enrollment
22nd of 52
50 · median 44
Started
2025
with 3 others
Phase 1
7 of 52
2 open now
Primary completion
2029-01
later than 29 of 30 live
Registered
26th of 52
by date
Lead sponsor
3 of 52
Shanghai Zhongshan Hospital

Among the 52 studies testing sintilimab in Carcinoma, Hepatocellular, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 29 of the 30 other live ones, and was the 26th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

27 of the 52 studies testing sintilimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing sintilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.

Read the detailed description

This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.

Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinoma
  • IBI310 in Combination with Bevacizumab and Sintilimab
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically/ confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
  2. Aged ≥18 years,≤75 years;
  3. performance status score of 0 or 1 point;
  4. Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
  5. No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
  6. At least 1 according to the Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
  7. Class A or B(≤7);
  8. Adequate organ and bone marrow function.
  9. Expected life time is over 12 weeks.
  10. Take effective measures
  11. Willing to attend the study and having given the ICF

Exclusion criteria

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
  2. History of hepatic encephalopathy or liver transplantation
  3. Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
  4. >2000 IU/ML or 10\^4 copies/ml;Untreated positive ;HbsAg and anti-HCV antibody were both positive
  5. History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
  6. Arteriovenous embolism within 6 months
  7. The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
  8. Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
  9. Uncontrolled hypertension
  10. Unrecovered AE(> grade 1) due to previous treatment
  11. Heart failure ( Classification III-IV), or poorly controlled arrhythmias
  12. History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  13. With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
  14. Active tuberculosis
  15. Infected with or syphilis
  16. Severe infections that are active or clinically poorly controlled
  17. Use of drugs within 4 weeks prior to initial dosing
  18. Receipt of within 4 weeks prior to randomization
  19. Significant traumatic injury or major surgical procedure within 28 days prior to randomization
  20. Other conditions that the investigator judged inappropriate for inclusion
  21. Prior immunotherapy or targeted therapy
  22. Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
  23. Pregnant or breast-feeding women
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single-Arm

    IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W

    Drug: IBI310(1mg/kg) · Drug: sintilimab · Drug: bevacizumab

Interventions

  • DrugIBI310(1mg/kg)

    IBI310 1mg/kg IV d1 Q6W

  • sintilimab 200 mg IV d1 Q3W

    Also known as: IBI308

  • bevacizumab 15 mg/kg IV d1,Q3W

    Also known as: IBI305

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Event, TEAE

    Safety

    Time frame: Any emergent adverse event from first dose through study completion, up to 2 years.

  2. Severe Adverse Event, SAE

    Safety

    Time frame: Any severe adverse event from first dose through study completion, up to 2 years.

  3. Objective response rate (ORR)

    efficacy

    Time frame: The proportion of patients with complete response or partial response, through study completion, up to 2 years

Secondary outcomes

  1. Duration of Response(DOR)according to RECIST V1.1 criteria

    efficacy

    Time frame: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

  2. Duration of Response(DOR)according to mRECIST criteria

    efficacy

    Time frame: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

  3. Disease Control Rate(DCR) according to RECIST V1.1 criteria

    efficacy

    Time frame: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years

  4. Disease Control Rate(DCR) according to mRECIST criteria

    efficacy

    Time frame: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years

  5. Objective response rate (ORR) according to mRECIST criteria

    efficacy

    Time frame: The proportion of patients with complete response or partial response, through study completion, an average of 2 years

  6. Progresison Free Survival(PFS)according to RECIST V1.1 criteria

    efficacy

    Time frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

  7. Progresison Free Survival(PFS)according to mRECIST criteria

    efficacy

    Time frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

  8. Overall survival (OS)

    efficacy

    Time frame: From the date of randomization until death from any cause, assessed up to 48 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2029, 46 months after the start.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's planned 46 months is close to that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start May 2022 → Mar 2025, primary completion Apr 2023 → Jan 2029 and completion Apr 2024 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
May 6, 2022
StartActual
Mar 6, 2025was May 2022
Primary completionEst.
Jan 2029was Apr 2023
CompletionEst.
Dec 2029was Apr 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in China
Show site
  • Zhongshan Hospital, Fudan University · Shanghai, China
Nov 17, 2026
Start date
May 2022→Mar 6, 2025 (actual)
Nov 17, 2026
Primary completion
Apr 2023→Jan 2029
Nov 17, 2026
Study completion
Apr 2024→Dec 2029
Nov 17, 2026
Enrollment
80→50
Nov 17, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAt least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria);, at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
Nov 17, 2026
Interventions
Changed IBI310(0.5mg/kg)→IBI310(1mg/kg). Removed Drug: IBI310(0.3mg/kg). Arms added: Single-Arm; arms removed: Arm A(IBI310 0.5mg/kg)·Arm B(IBI310 0.3mg/kg)
Nov 17, 2026
Primary outcomes
1 time frame changed, 2 added
What changed in the outcomes
  • AddedTreatment Emergent Adverse Event, TEAETime frame: Any emergent adverse event from first dose through study completion, up to 2 years.
  • AddedSevere Adverse Event, SAETime frame: Any severe adverse event from first dose through study completion, up to 2 years.
  • Time frameObjective response rate (ORR)The proportion of patients with complete response or partial response, through study completion, an average of 3 years → The proportion of patients with complete response or partial response, through study completion, up to 2 years
Nov 17, 2026
Secondary outcomes
3 edited, 5 time frame changed, 2 removed
What changed in the outcomes
  • EditedTime to ProgressionProgresison Free Survival(TTPPFS)according to RECIST V1.1 criteriaTime frame: From date of randomization until the date of first documented progression, up to 48 months → From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
  • EditedTime to ProgressionProgresison Free Survival(TTPPFS)according to mRECIST criteriaTime frame: From date of randomization until the date of first documented progression, up to 48 months → From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
  • ChangedBefore Progresison Free Surviva(PFS)according to RECIST V1.1 criteriaNow Objective response rate (ORR) according to mRECIST criteriaTime frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months → The proportion of patients with complete response or partial response, through study completion, an average of 2 years
  • RemovedProgresison Free Surviva(PFS)according to mRECIST criteriaTime frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months
  • RemovedImmune Best Overall Response(iBOR)according to iRECIST criteriaTime frame: The best timepoint response recorded from the start of the study treatment until the end of treatment, taking into account any requirement for confirmation, through study completion, an average of 3 years
  • Time frameDuration of Response(DOR)according to RECIST V1.1 criteriaFrom date of randomization until the date of first documented progression, up to 48 months → From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
  • Time frameDuration of Response(DOR)according to mRECIST criteriaFrom date of randomization until the date of first documented progression, up to 48 months → From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
  • Time frameDisease Control Rate(DCR) according to RECIST V1.1 criteriaThe percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, an average of 3 years → The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
  • Time frameDisease Control Rate(DCR) according to mRECIST criteriaThe percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, an average of 3 years → The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
  • Time frameOverall survival (OS)From date of randomization until death from any cause,through study completion, an average of 3 years → From the date of randomization until death from any cause, assessed up to 48 months.
Nov 17, 2026
Title
A Clinical Study to Observe the Effectivenesson Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular CarcinomaHCC
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Recruiting
    1 site added — first site in China
    Show site
    • Zhongshan Hospital, Fudan University · Shanghai, China
    Start date May 2022→Mar 6, 2025 (now actual)
    Primary completion Apr 2023→Jan 2029
    Study completion Apr 2024→Dec 2029
    Enrollment 80→50
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAt least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria);, at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
    Primary outcomes 1 time frame changed, 2 added
    What changed in the outcomes
    • AddedTreatment Emergent Adverse Event, TEAETime frame: Any emergent adverse event from first dose through study completion, up to 2 years.
    • AddedSevere Adverse Event, SAETime frame: Any severe adverse event from first dose through study completion, up to 2 years.
    • Time frameObjective response rate (ORR)The proportion of patients with complete response or partial response, through study completion, an average of 3 years → The proportion of patients with complete response or partial response, through study completion, up to 2 years
    Secondary outcomes 3 edited, 5 time frame changed, 2 removed
    What changed in the outcomes
    • EditedTime to ProgressionProgresison Free Survival(TTPPFS)according to RECIST V1.1 criteriaTime frame: From date of randomization until the date of first documented progression, up to 48 months → From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
    • EditedTime to ProgressionProgresison Free Survival(TTPPFS)according to mRECIST criteriaTime frame: From date of randomization until the date of first documented progression, up to 48 months → From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
    • ChangedBefore Progresison Free Surviva(PFS)according to RECIST V1.1 criteriaNow Objective response rate (ORR) according to mRECIST criteriaTime frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months → The proportion of patients with complete response or partial response, through study completion, an average of 2 years
    • RemovedProgresison Free Surviva(PFS)according to mRECIST criteriaTime frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months
    • RemovedImmune Best Overall Response(iBOR)according to iRECIST criteriaTime frame: The best timepoint response recorded from the start of the study treatment until the end of treatment, taking into account any requirement for confirmation, through study completion, an average of 3 years
    • Time frameDuration of Response(DOR)according to RECIST V1.1 criteriaFrom date of randomization until the date of first documented progression, up to 48 months → From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
    • Time frameDuration of Response(DOR)according to mRECIST criteriaFrom date of randomization until the date of first documented progression, up to 48 months → From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
    • Time frameDisease Control Rate(DCR) according to RECIST V1.1 criteriaThe percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, an average of 3 years → The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
    • Time frameDisease Control Rate(DCR) according to mRECIST criteriaThe percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, an average of 3 years → The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
    • Time frameOverall survival (OS)From date of randomization until death from any cause,through study completion, an average of 3 years → From the date of randomization until death from any cause, assessed up to 48 months.
    Interventions Changed IBI310(0.5mg/kg)→IBI310(1mg/kg). Removed Drug: IBI310(0.3mg/kg). Arms added: Single-Arm; arms removed: Arm A(IBI310 0.5mg/kg)·Arm B(IBI310 0.3mg/kg)
    Title A Clinical Study to Observe the Effectivenesson Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular CarcinomaHCC
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05363722
Responsible party
Sponsor
First posted
May 6, 2022
Start date
Mar 6, 2025
Primary completion
Jan 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Chengfeng Liu
Contact
liu.chengfeng@zs-hospital.sh.cn
+86 15201927474
Zhenggang Ren
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion